Miocamycin

DB13287ApprovedSmall molecule

Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to... It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to...

Mechanism: Miocamycin is a macrolide antibiotic, which inhibits bacterial protein synthesis by binding the 50S ribosomal subunit (23S rRNA region), blocking elongation.
Curator reviewed · 1 reference
Formula / weight: C₄₅H₇₁NO₁₇ · 898.053 g/mol (avg)
Also known as: Midecamycin acetate

Resolves to

Compound

UNII3T48CPS7U2CAS55881-07-7ChEMBLCHEMBL1091024ChEBI749137PubChem5282188

Clinical / RWD

RxNorm236200ATCJ01FA11

Structure

InChIKeyGQNZGCARKRHPOH-RQIKCTSVSA-NSMILES

CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C

What you can answer from here — as of September 24, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

290Drug interactionsStructured to mechanism, not free text

9Structured indicationsCondition, population, route and combination as fields, not prose

18Marketed productsAcross 1 country and 3 labellers

1ATC codeIncluding every combination product, plus 12 drug categories

6+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Miocamycin, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account